AT-55 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

INTRODUCTION: Bevacizumab (BEV) is widely used in recurrent glioblastoma, alone or in combination with other agents. There is however no controlled trial to support this use. MATERIAL AND METHODS: In a Dutch multicenter randomized phase II study patients were assigned to BEV 10 mg/kg day 1, 15 and 2...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Taal, Walter, Enting, Roelien, Taphoorn, Martin, Smits, Marion, Dubbink, Hendrikus, Beerepoot, Laurens, Hanse, Monique, Bralten, Linda, Oosterkamp, Hendrika, Walenkamp, Annemiek, Buter, Jan, Honkoop, Aafke, Boerman, Dolf, de Vos, Filip, Bromberg, Jacoline, Vernhout, Rene, van der Holt, Bronno, van den Bent, Martin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2014
Soggetti:
Adult Clinical Trials
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217835/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.54
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi